C

Clinical Research Puerto Rico | San Juan, PR

Research site
(Unclaimed)
Location
359 De Diego Avenue Suite 501, San Juan, Puerto Rico, United States of America
Site insights

Top conditions

HIV Infections (24 trials)

Immunologic Deficiency Syndromes (9 trials)

Acquired Immunodeficiency Syndrome (9 trials)

Hepatitis C (6 trials)

Infections (5 trials)

Top treatments

Emtricitabine
Upadacitinib
Tenofovir Disoproxil Fumarate
Ritonavir
Rilpivirine
TDF
Tenofovir Alafenamide
TAF
Efavirenz
Ribavirin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

12 of 67
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting
HIV Infections
Drug: Antiretroviral Therapy
Drug: Zinlirvimab
Locations recently updated

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling
Human Immuno-deficiency Virus (HIV) Disease
Drug: Budigalimab
Drug: Placebo for Budigalimab
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Placebo
Drug: Upadacitinib

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase I study to assess the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine given as a booster to those previously vaccinated against...

Active, not recruiting
COVID-19
Healthy
Drug: GLS-5310 (Group 2)
Drug: GLS-5310 (Group 4)

Phase I study of the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2 (COVID-19)

Not yet enrolling
Healthy
Covid19
Biological: Placebo
Biological: GLS-5130

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Paclitaxel
Drug: Gemcitabine

Trial sponsors

Gilead Sciences logo

Gilead Sciences (27 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems